Страна: США
мова: англійська
Джерело: NLM (National Library of Medicine)
DOXAZOSIN MESYLATE (UNII: 86P6PQK0MU) (DOXAZOSIN - UNII:NW1291F1W8)
NCS HealthCare of KY, Inc dba Vangard Labs
DOXAZOSIN MESYLATE
DOXAZOSIN 1 mg
ORAL
PRESCRIPTION DRUG
Doxazosin tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). Doxazosin may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with doxazosin monotherapy. Doxazosin provides rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. Sustained improvements with doxazosin were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. Doxazosin tablets are also indicated for the treatment of hypertension. Doxazosin may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibitors. Doxazosin
Doxazosin Tablets, USP are available as tablets for oral administration. Each tablet contains doxazosin mesylate equivalent to 1 mg, 2 mg, 4 mg or 8 mg of doxazosin. The 1 mg are available as white to off-white, round, biconvex tablets debossed with M over D9 on one side of the tablet and scored on the other side. They are available as follows: NDC 0615-5536-39 blisterpacks of 30 tablets The 2 mg are available as pink, round, biconvex tablets debossed with M over D10 on one side of the tablet and scored on the other side. They are available as follows: NDC 0615-6570-39 blisterpacks of 30 tablets The 4 mg are available as blue, round, biconvex tablets debossed with M over D11 on one side of the tablet and scored on the other side. They are available as follows: NDC 0615-6571-39 blisterpacks of 30 tablets The 8 mg are available as purple, round, biconvex tablets debossed with M over D12 on one side of the tablet and scored on the other side. They are available as follows: NDC 0615-5537-39 blisterpacks of 30 tablets Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. PHARMACIST: Detach Patient Information Leaflet at each perforation and give leaflet to patient.
Abbreviated New Drug Application
DOXAZOSIN- DOXAZOSIN MESYLATE TABLET NCS HEALTHCARE OF KY, INC DBA VANGARD LABS ---------- DOXAZOSIN TABLETS, USP 1 MG, 2 MG, 4 MG AND 8 MG RX ONLY 1 DESCRIPTION Doxazosin mesylate is a quinazoline compound that is a selective inhibitor of the alpha subtype of alpha adrenergic receptors. The chemical name of doxazosin mesylate is 1-(4-amino-6,7-dimethoxy-2- quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate. The molecular formula for doxazosin mesylate is C H N O • CH O S and the molecular weight is 547.6. It has the following structure: Doxazosin mesylate is freely soluble in dimethylsulfoxide, soluble in dimethylformamide, slightly soluble in methanol, ethanol, and water (0.8% at 25°C), and very slightly soluble in acetone and methylene chloride. Doxazosin Tablets, USP for oral administration, contain 1 mg, 2 mg, 4 mg or 8 mg of doxazosin as doxazosin mesylate. In addition, each tablet also contains the following inactive ingredients: anhydrous lactose, colloidal silicon, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate and sodium starch glycolate. The 2 mg tablets also contain D&C Red No. 30 Aluminum Lake, the 4 mg tablets contain FD&C Blue No. 2 Aluminum Lake, and the 8 mg tablets contain D&C Red No. 30 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake. CLINICAL PHARMACOLOGY PHARMACODYNAMICS Benign Prostatic Hyperplasia (BPH) Benign prostatic hyperplasia (BPH) is a common cause of urinary outflow obstruction in aging males. Severe BPH may lead to urinary retention and renal damage. A static and a dynamic component contribute to the symptoms and reduced urinary flow rate associated with BPH. The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not 1 (EACH TABLET CONTAINS DOXAZOSIN MESYLATE EQUIVALENT TO 1 MG , 2 MG , 4 MG OR 8 MG OF DOXAZOSIN) 1 23 25 5 5 4 3 correlate well with the size of th Прочитайте повний документ